Thyrocare Technologies has allotted 10,61,07,794 equity shares of Rs 10 each under bonus issue in ratio of 2:1. Post allotment, the paid up equity share capital has increased to 15,91,61,691 equity shares of Rs 10 each. Powered by Capital Market - Live News

Thyrocare Technologies announced that Nitin Chugh, Chief Commercial Officer and part of the Senior Management Personnel of the company has resigned with effect from 30 November 2025. Powered by Capital Market - Live News

Docon Technologies Private Limited (�Docon�), Promoter of Thyrocare Technologies has sold 53,32,860 equity shares of the Company through market trades on 24th October 2025 for an aggregate gross consideration of Rs. 667.69 crore (rounded off), at an average price of approximately Rs. 1,252.03 per share (rounded off). The number of shares sold constitutes approximately 10% of the total paid-up capital of the Company. Following this transaction, Docon continues to be a promoter of the Company. Post this transaction, the promoter shareholding in the Company stands reduced to 60.93% from the pre-transaction shareholding of 70.98%.Powered by Capital Market - Live News

The Board of Thyrocare Technologies has approved issuance of bonus shares in the proportion of 2:1, i.e. 2 bonus equity shares of Rs 10 each for every 1 fully paid-up equity share held as on the record date. Also, the board has declared an interim dividend of INR 7 per equity share of the face value of Rs 10 each, pre-bonus issuancePowered by Capital Market - Live News

Net profit of Thyrocare Technologies rose 79.94% to Rs 47.99 crore in the quarter ended September 2025 as against Rs 26.67 crore during the previous quarter ended September 2024. Sales rose 22.09% to Rs 216.53 crore in the quarter ended September 2025 as against Rs 177.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales216.53177.36 22 OPM %32.9527.06 - PBDT74.0949.85 49 PBT62.5836.78 70 NP47.9926.67 80 Powered by Capital Market - Live News